Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $34.1 million.

  • CG Oncology's Non-Current Assets rose 862711.0% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 127957.75%. This contributed to the annual value of $587000.0 for FY2024, which is 8866.14% down from last year.
  • As of Q3 2025, CG Oncology's Non-Current Assets stood at $34.1 million, which was up 862711.0% from $28.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Non-Current Assets ranged from a high of $34.1 million in Q3 2025 and a low of $391000.0 during Q3 2024
  • Over the past 3 years, CG Oncology's median Non-Current Assets value was $2.9 million (recorded in 2023), while the average stood at $12.1 million.
  • As far as peak fluctuations go, CG Oncology's Non-Current Assets plummeted by 8866.14% in 2024, and later skyrocketed by 862711.0% in 2025.
  • CG Oncology's Non-Current Assets (Quarter) stood at $5.2 million in 2023, then tumbled by 88.66% to $587000.0 in 2024, then soared by 5713.12% to $34.1 million in 2025.
  • Its Non-Current Assets stands at $34.1 million for Q3 2025, versus $28.4 million for Q2 2025 and $27.0 million for Q1 2025.